FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy

Pfizer should partner with Sanofi

Tools

It's day three of the Pfizer-Sanofi merger watch. Sanofi-Aventis shares are up 5.5 percent on continued rumors of a Pfizer investment in its business. Now, experts are saying that a Sanofi acquisition wouldn't be prudent for Pfizer--but a partnership would.

If Pfizer just bought a stake in Sanofi, it could share in the French company's revenues. Sanofi would get access to Pfizer's U.S. sales force. And the companies wouldn't have to get the French government's blessing on this sort of deal--a blessing that might be hard to come by.

- read the report from Fortune

Related Articles:
Pfizer-Sanofi match not made in heaven? Report
Sanofi stock up on Pfizer buyout talk. Report
Pfizer, Wyeth merger bad idea? Report

Read more on: Pfizer | Sanofi-Aventis


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FiercePharma Email Newsletter:

More stories about Pfizer   Wyeth   Sanofi-Aventis   Mergers and Acquisitions